New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000) As a leader in neuroscience, Teva remains committed to helping address unmet needs in the treatment of schizophrenia through scientific and clinical advances that support optimal treatment options and...

Teva to Present at the Bank of America 2024 Global Healthcare Conference TEL AVIV, Israel, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the...

Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference TEL AVIV, Israel, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the...

Teva Announces Strong Growth in Second Quarter Revenues mainly driven by Generics Products in All Regions and AUSTEDO®; Raises 2024 Financial Guidance For an accessible version of this Press Release, please visit www.tevapharm.com Q2 2024 revenues of $4.2 billion reflecting an increase of 7% in U.S. dollars or 11% in local...